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Abstract 
Poor oxygenation of solid tumours has been linked with resistance to chemo- and radio-therapy and 
poor patient outcomes, hence non-invasive imaging of oxygen supply and demand in tumours could 
improve disease staging and therapeutic monitoring. Optoacoustic tomography (OT) is an emerging 
clinical imaging modality that provides static images of endogenous haemoglobin concentration and 
oxygenation. Here, we demonstrate oxygen enhanced (OE)-OT, exploiting an oxygen gas challenge to 
visualise the spatiotemporal heterogeneity of tumour vascular function. We show that tracking 
oxygenation dynamics using OE-OT reveals significant differences between two prostate cancer models 
in nude mice with markedly different vascular function (PC3 & LNCaP), which appear identical in static 
OT. LNCaP tumours showed a spatially heterogeneous response within and between tumours, with a 
substantial but slow response to the gas challenge, aligned with ex vivo analysis, which revealed a 
generally perfused and viable tumour with marked areas of haemorrhage. PC3 tumours had a lower 
fraction of responding pixels compared to LNCaP with a high disparity between rim and core response. 
While the PC3 core showed little or no dynamic response, the rim showed a rapid change, consistent 
with our ex vivo findings of hypoxic and necrotic core tissue surrounded by a rim of mature and perfused 
vasculature. OE-OT metrics are shown to be highly repeatable and correlate directly on a per-tumour 
basis to tumour vessel function assessed ex vivo. OE-OT provides a non-invasive approach to reveal the 
complex dynamics of tumour vessel perfusion, permeability and vasoactivity in real time. Our findings 
indicate that OE-OT holds potential for application in prostate cancer patients, to improve delineation 
of aggressive and indolent disease as well as in patient stratification for chemo- and radio-therapy. 
Key words: optoacoustic, imaging, oxygenation, angiogenesis, hypoxia. 
Introduction 
Angiogenesis is required for delivery of oxygen 
and nutrients to the proliferating tumour volume 
beyond ~1mm3 1. The chaotic and tortuous nature of 
the resulting vasculature leads to substantial 
intra-tumoural heterogeneity in vascular density and 
function2, respectively leading to diffusion- and 
perfusion-limited hypoxia3. These hypoxic stresses 
increase tumour heterogeneity4 and result in poor 
prognosis5,6 through increased chemo- and 
radio-resistance2,7, particularly in cancers of hormone 
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sensitive tissues such as the prostate6. Non-invasive 
imaging of oxygen supply and demand in prostate 
cancer could therefore improve diagnosis and staging, 
by delineating aggressive from indolent disease, and 
assist with therapeutic decision making, by 
identifying tumours with reduced vascular function, 
which limits delivery of chemotherapy and decreases 
efficacy of radiotherapy. 
Magnetic resonance imaging (MRI)-based 
approaches such as blood oxygen level dependent 
(BOLD) and oxygen enhanced (OE) MRI8 have been 
shown to correlate with tissue oxygen partial pressure 
(pO2) and histological markers of hypoxia9,10. 
Combined T2* and T1 contrast11 as well as breathing 
gas challenges12,13 have previously been applied in 
prostate cancer, and the advantages of oxygen 
contrast in comparison to exogenous contrast 
enhancement in functional studies has been 
evaluated14. However, these functional MRI 
techniques suffer from intrinsically low sensitivity, 
poor spatial resolution, and in case of BOLD, signals 
that may be confounded by several biological 
factors15,16. Positron emission tomography (PET) 
agents for hypoxia visualisation are also available17, 
but these measurements are limited by the inherently 
low spatial resolution of PET and risks related to 
radioisotope administration. Hence, while MRI and 
PET approaches hold some promise, there remains an 
unmet clinical need for validated imaging biomarkers 
of vascular density and function, as well as vascular 
heterogeneity, that can be measured cost effectively at 
high spatial and temporal resolution18. 
 Optoacoustic tomography (OT) is an emerging 
imaging modality19,20 that is currently in clinical 
trials20,21 and has the potential to fulfil this unmet 
need. OT reveals the distribution of tissue optical 
absorption coefficient in real time with a spatial 
resolution of ~190μm at 3cm penetration depth22. 
Since the absorption spectra of oxy- and 
deoxy-haemoglobin are distinct, acquiring OT data at 
multiple wavelengths makes it possible to derive 
images of haemoglobin concentration and oxygena-
tion. OT has recently been shown qualitatively to: 
visualise and quantify microvasculature in 3D with 
high resolution23,24; monitor vascular development 
during tumour growth25–27; detect response to 
vascular targeted therapies28,29 and predict 
radiotherapy response30. OT has also been paired with 
contrast enhanced ultrasound31,32 to discriminate 
cellular necrosis from blood lakes32. While promising, 
these studies take only a static readout and quantify 
mean tumour values hence lack quantitative insight 
into vascular dynamics or the spatial heterogeneity of 
vascular function within or between tumours. We 
hypothesized that by studying the spatiotemporal 
response of the tumour vasculature to an oxygen 
challenge using OT, we could gain greater insight into 
tumour vessel dynamics. Here, we demonstrate that 
oxygen enhanced (OE) OT provides a highly 
repeatable and robust readout of tumour vascular 
function, studying both spatial heterogeneity and 
evolution during tumour growth, which is relevant in 
the context of prostate cancer staging. We present for 
the first time a significant per tumour correlation 
between the tumour OE-OT dynamics and 
histopathological measures including an ex vivo 
Hoechst 33342 dye uptake, which serves to model 
delivery of a small molecule agent. We find that 
OE-OT can delineate two prostate cancer xenograft 
models with markedly different vascular 
characteristics that appear identical in terms of their 
static OT haemoglobin oxygenation measurement: the 
androgen-independent, aggressive, poorly 
differentiated and highly metastatic PC333; and the 
androgen-sensitive, slow-growing, highly 
differentiated, haemorrhagic LNCaP34. We provide 
the first biological validation of OE-OT as a technique 
for dynamic visualization of the spatial heterogeneity 
in tumour vascular function. 
Methods 
Animal Experiments 
All animal procedures were conducted in 
accordance with project (70-8214) and personal license 
(IDCC385D3) issued under the United Kingdom 
Animals (Scientific Procedures) Act, 1986 and were 
approved locally under compliance form number 
CFSB0671. Subcutaneous prostate tumours were 
established in male BALB/c nude mice (Charles 
River): Two prostate adenocarcinoma cell lines 
(obtained from CRUK Cambridge Institute 
biorepository), suspended in PBS and Matrigel 
(Corning) in equal parts, were implanted 
subcutaneously in two different cohorts: PC3 (n=33 
mice, 1.5x106 cells, up to 200µL in right flank) and 
LNCaP (n=15 mice, 1.5x106 cells, up to 100µL in both 
flanks). Authentication using Genemapper ID v3.2.1 
(Genetica) by STR Genotyping (1/2015) showed 94% 
match in both cases. Tumour growth was monitored 
regularly by callipers (Figure S1) and by imaging at 
three time points; mice were sacrificed at intermediate 
time-points and at the study end point, before 
tumours reached 10% body weight. Volume matching 
within tumour type was performed as follows: the 
first imaging session was performed when tumours 
reached > 30mm3; the intermediate imaging session 
was performed at the mid-point for growth; and the 
final imaging session was taken at the limits of ethical 
approval, based on tumour volume or animal welfare. 
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Exclusion criteria for mice are detailed in the 
Supplementary Methods. 
Optoacoustic Imaging 
For optoacoustic imaging, a MultiSpectral 
Optoacoustic Tomography (MSOT) inVision 256-TF 
small animal imaging system (iThera Medical GmbH) 
was used35. Briefly, a tunable optical parametric 
oscillator (OPO) pumped by an Nd:YAG laser 
provides excitation pulses with a duration of 9ns at 
wavelengths from 660nm to 1200nm at a repetition 
rate of 10Hz with a wavelength tuning speed of 10ms 
and a peak pulse energy of 90mJ at 720nm. Ten arms 
of a fiber bundle provide uniform illumination of a 
ring-shaped light strip of approximately 8mm width. 
For ultrasound detection, 256 toroidally focused 
ultrasound transducers with a center frequency of 
5MHz (60% bandwidth), organized in a concave array 
of 270 degree angular coverage and a radius of 
curvature of 4cm, are used.  
Mice were prepared according to our standard 
operating procedure36. Briefly, mice were 
anaesthetised using <3% isoflurane and placed in a 
custom animal holder (iThera Medical), wrapped in a 
thin polyethylene membrane, with ultrasound gel 
(Aquasonic Clear, Parker Labs) used to couple the 
skin to the membrane. The holder was then placed 
within the MSOT system and immersed in degassed 
water maintained at 36°C. Mice were allowed to 
stabilise for 15 minutes within the system prior to 
initialisation of the scan and their respiratory rate was 
then maintained in the range 70-80bpm with ~1.8% 
isoflurane concentration for the entire scan. 
Manipulation of the breathing gas between medical 
air (21% oxygen) and pure oxygen (100% oxygen) was 
performed manually using separate flow meters 
according to the schedule in Figure 1A. When 
tumours were established on both flanks, the imaging 
field of view was placed within the larger tumour at 
the time of the first imaging session, unless both 
tumours were in the same plane. Images were 
acquired through the centre of the tumour using 15 
wavelengths between 700nm and 880nm and an 
average of 7 pulses per wavelength; a single slice 
acquisition was 11.5s in duration. A subset of the PC3 
cohort (n=8) were imaged twice, with 24h between the 
scans to allow for full recovery from anaesthesia, to 
assess the repeatability of the oxygen challenge data. 
The small molecule (616Da) dye Hoechst 33342 
(Thermo Fisher Scientific) extravasates into tumour 
tissue, giving an indication of vascular permeability 
and perfusion37, important for the assessment of the 
vascular function38,39 and simulating the uptake of a 
small molecule therapeutic agent. Mice were injected 
intravenously in the tail vein with 120μL of Hoechst 
33342 for a 20g mouse at 2.5mg/ml in PBS (yielding 
15mg/kg) two minutes before sacrifice40 by cervical 
dislocation. Immediately after sacrifice, tumours were 
excised.  
Magnetic Resonance Imaging  
Mice bearing PC3 (n=7) and LNCaP (n=3) 
tumours underwent magnetic resonance imaging 
(MRI) on a 9.4T Agilent MRI system running VnmrJ 
3.1, using a quadrature transmit/receive millipede 
volume coil (Agilent, inc) of 38mm inner diameter 
after the OE-OT scan. The same anaesthesia and 
oxygen challenge protocol as for optoacoustic 
imaging experiments was used. The mouse was 
cannulated before being placed in the holder and its 
temperature was monitored using a rectal probe, 
stabilized to 37OC using air heating system. BOLD 
MRI data were then acquired (see Supplementary 
Methods for details). After the oxygen challenge the 
animals were injected with the Gadolinium-based 
Gadovist agent (Bayer, 200µmol/kg) through the 
intravenous cannula. DCE-MRI data were then 
acquired (see Supplementary Methods for details). 
The mice then underwent optoacoustic imaging and 
the results were compared on a per-tumour basis. 
Oxylite Measurements 
An invasive Oxylite pO2 probe (Oxford 
Optronics Ltd.) was used to assess changes in local 
oxygen partial pressure in response to the oxygen 
challenge in PC3 tumour bearing mice (n=6) as 
detailed in the Supplementary Methods.  
Histopathologic Tumour Analysis 
Tumours from the two cohorts were either 
mounted on a cork base using OCT solution (VWR 
Chemicals) and snap frozen in an isopentane bath 
cooled on dry ice for fluorescence analysis or divided 
into two (parallel to the imaging plane) with the other 
half being fixed in neutral buffered 10% formalin 
(24h) for haematoxylin and eosin (H&E) staining. 
Formalin fixed, paraffin embedded (FFPE) tumours 
were sectioned with 3µm thickness at 4 equally 
spaced levels. Additionally, immunohistochemistry 
was performed. Consecutive adjacent sections from 5 
PC3 and 5 LNCaP tumours in the centre were stained 
with CD31 (anti-mouse, BD Biosciences, 553370) and 
alpha smooth muscle actin (ASMA) (anti-mouse, 
Abcam, ab5694) to indicate vessel density and smooth 
muscle coverage respectively. Further sections were 
stained with CAIX (anti-human, BioScience Slovakia, 
AB1001) to indicate hypoxic regions. 
Frozen blocks were sectioned with 6µm 
thickness at 4 equally spaced levels. To indicate 
vascular density, immunofluorescence staining of 
CD31 was performed using anti-mouse CD31 primary 
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antibody (555370, BD Biosciences) and an 
AlexaFluor647 conjugated anti-rat secondary 
antibody (A21472, Invitrogen Molecular Probes). 
Sections were mounted in a DAPI-free mounting 
media (S36936 SlowFade, Life Technologies) and 
scanned using a confocal microscope with laser 
wavelengths of 350nm (for Hoechst) and 633nm 
(Leica TCS SP5, Leica Microsystems). In each section, 
up to 10 fields of view (1.02mm x 1.02mm) were 
randomly selected and imaged using both colour 
channels.  
Image and Statistical Analysis 
All image analysis was performed in MATLAB 
(Mathworks) using custom software unless otherwise 
stated.  
Optoacoustic image reconstruction was 
performed using an acoustic backprojection algorithm 
(iThera Medical) with an electrical impulse response 
correction, to account for the frequency dependent 
sensitivity profile of the transducers41. Images were 
reconstructed with a pixel size of 75μm x 75μm, which 
is approximately equal to half of the in-plane 
resolution of the InVision 256-TF.  
Regions of interest (ROIs) were drawn manually 
around the tumours (excluding the skin) and a 
healthy tissue region around the spine in the 800nm 
(isosbestic) image of the first frame of the oxygen 
challenge data (Figure S2). The tumour size is taken as 
the area of the ROI, which correlates directly to 
calliper measurements (r=0.81, p<0.0001; n=22). The 
optoacoustic spectrum was averaged across all pixels 
in the ROIs and a pseudoinverse matrix inversion 
(pinv function in MATLAB 2014A) was used for 
spectral unmixing of the relative weights of oxy- 
[HbO2] and deoxy-haemoglobin [Hb] (example 
images shown in Figure S2). Optoacoustic 
tomography is only able to accurately resolve absolute 
SO2 if the recorded signal is directly related to the 
absorbed optical energy distribution, which requires 
knowledge of the light fluence distribution, system 
response and Grueneisen parameter42. We therefore 
denote the oxygenation metric derived in this study as 
an apparent metric, SO2MSOT rather than absolute SO2. 
SO2MSOT was computed as the ratio of oxygenated 
[HbO2] to total haemoglobin [HbO2+Hb]. Rim-core 
segmentation was performed by successively 
shrinking the tumour ROI inwards in 0.5mm steps. 
The two outer regions are referred to as the ‘Rim’, 
while the remaining part of the tumour is the ‘Core’ in 
the bulk analysis, based on qualitative evaluation of 
our histopathology data. A more detailed depth 
dependent analysis was performed in addition on 
large tumours (where at least 5 separate regions exist) 
with the outer 4 regions of 0.5mm thickness analysed 
individually as contributing to the ‘Rim’ and the 
remaining as the ‘Core’.  
Kinetic SO2MSOT profiles for each tumour were 
smoothed using a moving average and analysed as 
shown in Figure 1A. Extracted metrics of baseline 
SO2MSOT values before [SO2MSOT(Air)] and after oxygen 
challenge [SO2MSOT(O2)] informed on the equilibrium 
status of the tumour. OE-OT metrics included: 
amplitude of signal change (ΔSO2MSOT); time to 
half-maximum (T1/2); and the ‘Responding Fraction’ 
(RF) of the tumour. RF was quantified by 
reconstructing the images on an array of 225μm x 
225μm pixels, for which spectral unmixing was 
performed on a per-pixel basis. A pixel was classified 
as ‘responding’ if the ΔSO2MSOT exceeded 0.03 
(insensitive to threshold value, see Figure S3) and RF 
was taken as the ratio of responding to total number 
of pixels. 
MRI data for T1 and T2* were fitted pixel-by-pixel 
to a monoexponential function to produce relaxation 
maps. The mean T2* value across all tumour pixels 
was extracted from BOLD data. DCE analysis was 
performed by applying the model of Tofts and 
Kermode43 to extract the mean Ktrans, the transfer 
coefficient of contrast agent into the tissue, describing 
tumour perfusion and permeability.  
Histopathological analysis of FFPE sections was 
performed on images scanned at 20x magnification 
using an Aperio ScanScope (Leica Biosystem) scanner 
to determine tumour necrotic fraction and ASMA 
vessel coverage. Confocal fluorescence microscopy 
images were used to quantify the vascular 
characteristics based on Hoechst uptake and CD31 
staining. Details of the quantification procedures can 
be found in the Supplementary Methods. Following 
image processing and identification of blood vessels44, 
the proportion of the derived total vessel area to total 
image area was quantified as ‘CD31 Vascular Area 
Fraction’ (CD31 VF). An estimate of the fraction of 
tumour receiving oxygen from the vessels (Perfused 
Area – CD31 PA) was calculated by expanding the 
identified vessels radially by 100μm, which is the 
approximate oxygen diffusion distance 45,46. Example 
images from each processing step are shown in Figure 
S4. The amount of Hoechst uptake (Hoechst Intensity 
– HI) was quantified as the average fluorescent signal 
intensity in the imaged tumour area.  
 Errors are shown as the standard error on the 
mean, unless otherwise stated. All statistical analyses 
were performed in GraphPad Prism 6 (Graphpad 
Software Inc.). Pearson rank test was performed to 
assess correlations between the optoacoustic 
tomography metrics and MRI or histopathology 
parameters. Paired two-tailed t-test compared the 
same tumour type; unpaired two-tailed t-test 
 Theranostics 2017, Vol. 7, Issue 10 
 
 
http://www.thno.org 
2904 
assuming unequal variances compared between 
tumour types. The significance of SO2MSOT changes in 
the time-series was assessed by a two-way 
un-matched ANOVA test. p<0.05 was considered 
significant. For correlations with histology, only the 
last OE-OT scan before sacrifice was used. For 
comparisons of OE-OT metrics between the tumour 
types all technical replicates (imaging sessions) not 
excluded from the study are included. The number of 
all technical (imaging sessions) and biological 
(number of tumours) replicates is quoted with each 
result, denoted with nt and nb respectively. Where a 
single n quoted, n is the number of biological 
replicates and no technical replicates were used. 
Results 
OE-OT delineates the vascular function of two 
prostate cancer xenografts 
 Application of the oxygen challenge resulted in 
clearly visible changes in the multispectral 
optoacoustic tomography (MSOT) derived oxygen 
saturation (SO2MSOT, Figure 1A). During the challenge, 
the measured absorption spectrum of both PC3 
(Figure 1B) and LNCaP (Figure 1C) tumours 
increased above 800 nm, where oxyhaemoglobin 
dominates. SO2MSOT of the healthy tissue around the 
spine shows a sharp, step function-like response to 
the oxygen challenge (Figure 1D) convolved with a 
slight downward drift (related to anaesthesia effects 
in healthy tissue36). The tumours, however, show a 
significantly lower baseline SO2MSOT(Air) (PC3: 
0.266±0.007 tumour vs. 0.488±0.010 healthy, nt=53, 
nb=30, p<0.0001; LNCaP: 0.286±0.011 tumour vs. 
0.512±0.019 healthy, nt=35, nb=17 p<0.0001) and a 
more gradual SO2MSOT response with a >4-fold longer 
time to half-maximum (Figure 1D,E; PC3: 
T1/2=300±23s tumour vs. 74±3s healthy, nt=44, nb=28, 
p<0.0001; LNCaP: T1/2=353±30s tumour vs. 84±5s 
healthy, nt=31, nb=15, p<0.0001). A similar shape of 
response is observed in independent pO2 
measurements (Figure S5) and in the raw oxy- and 
deoxy-haemoglobin data (Figure S6A,B). 
Interestingly, the total haemoglobin (THb) signal 
shows evidence of a change in the haemoglobin 
concentration in both tumour (Figure S6C) and 
healthy (Figure S6D) vasculature at the time points of 
the gas switch, which could arise due to the 
vasoconstrictive effect of oxygen breathing. Neither 
SO2MSOT nor THb in the tumour were observed to 
change over a similar time course without the oxygen 
challenge (Figure S6E, F).  
OE-OT metrics show high repeatability 
We assessed the repeatability of our metrics by 
performing a second OE-OT study 24 hours after the 
first in a subset of PC3 tumours (Figure S7A). 
Significant correlations between test and retest 
(Figure S7B) were found for SO2MSOT(O2) (r=0.76, 
p<0.01; n=8), Responding Fraction RF (r=0.96, 
p<0.001; n=8) and ΔSO2MSOT (r=0.89, p<0.01; n=8), 
indicating good repeatability of these OE-OT metrics. 
T1/2 could not always be robustly computed so was 
considered the least repeatable OE-OT metric. The 
static SO2MSOT metrics of THb (r=0.18, p=0.70; n=7) 
and SO2MSOT(Air) (r=0.64, p=0.09; n=8), show little or 
no correlation between test and retest, indicating poor 
repeatability for these metrics. Dynamic OE-OT 
metrics may therefore be more robust than static OT 
for longitudinal studies. 
 
 
Figure 1. Temporal evolution of the oxygen enhanced optoacoustic tomography (OE-OT) signal. An example kinetic curve taken from a PC3 tumour subject to an 
oxygen gas challenge is shown in (A). The metrics extracted from the OE-OT data illustrated in (A) are: baseline SO2MSOT values before [SO2MSOT(Air)] and after the oxygen 
challenge [SO2MSOT(O2)]; amplitude of signal change (ΔSO2MSOT); and time to half-maximum (T1/2). Averaged spectral changes for PC3 and LNCaP tumours are shown in (B) and 
(C) respectively, while kinetic profiles of SO2MSOT averaged across all healthy tissue ROIs and tumour xenograft ROIs are shown in (D) and (E) respectively, with standard error 
of the mean indicated by the shaded envelope (nt=53, nb=30 PC3, nt=35, nb=17 LNCaP). 
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OE-OT provides spatiotemporal insight not 
available using static OT 
 In order to examine the ability of OE-OT to 
provide greater insight into tumour vascular 
dynamics and heterogeneity, we first compared the 
spatial distribution (Figure 2A) and mean values 
(Figure 2B) of static OT [THb, SO2MSOT(Air)] and 
dynamic OE-OT [SO2MSOT(O2), Responding Fraction 
RF, ΔSO2MSOT] metrics between the two tumour types. 
LNCaP tumours showed substantial aggregation of 
blood near the skin and a significantly higher THb 
 
Figure 2. OT and OE-OT signals are spatially heterogeneous in PC3 and LNCaP tumours. (A) Representative images of PC3 (left) and LNCaP (right) tumours 
showing the spatial distribution of total haemoglobin (THb), baseline oxygen saturation before the oxygen challenge [SO2MSOT(Air)] and the OE-OT metrics of: oxygen 
saturation after the oxygen challenge [SO2MSOT(O2)]; responding fraction (RF), which indicates the distribution of responding and non-responding pixels; and the amplitude of 
the signal change in responding pixels (ΔSO2MSOT). All OE-OT metrics are significantly different between the two tumour types, highlighting vascular differences not visible in the 
static picture. Black arrows indicate responding pixels in the PC3 tumour core, white arrows indicate response of haemorrhagic regions in LNCaP tumours. (B) Quantification 
of the mean tumour values for each optoacoustic metric studied. Each point represents the mean of the given metric over the tumour in a technical replicate. * p<0.05, ** 
p<0.01, *** p<0.001 by unpaired two-tailed t-test (unequal variances), nt=53, nb=30 PC3, nt=35, nb=17 LNCaP. Box between 25th and 75th percentile, line at median. 
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signal than the PC3 (149±12, nt=35, nb=17 LNCaP vs. 
28.7±1.6, nt=53, nb=30 PC3; p<0.0001), consistent with 
the haemorrhagic phenotype. The static measurement 
of SO2MSOT(Air), commonly used in the literature, 
suggests both tumours have similar vascular 
oxygenation on average (Figure 2B; PC3 0.265±0.007, 
nt=53, nb=30vs. LNCAP 0.283±0.012, nt=35, nb=17; 
p=0.22). Conversely, application of our OE-OT 
approach reveals highly significant differences 
between the tumours: the mean SO2MSOT(O2), RF and 
ΔSO2MSOT are all significantly lower for PC3 than 
LNCaP tumours (Figure 2B; SO2MSOT(O2)=0.308±0.009 
vs. 0.370±0.016, p=0.002; RF=0.53±0.02 vs. 0.63±0.05, 
p=0.04, and ΔSO2MSOT=0.041±0.005 vs. 0.087±0.011, 
p=0.0005; nt=53, nb=30 and nt=35, nb=17 for PC3 and 
LNCaP respectively). 
Interestingly, the spatial distribution of ΔSO2MSOT 
frequently shows high oxygenation change in regions 
that have relatively low THb across both tumour 
types. The pixels classed as non-responding (Figure 
2A, RF and ΔSO2MSOT) tend to be present primarily in 
the core of the PC3 tumours (black arrows, Figure 2A), 
whereas the LNCaP tumour response is more 
heterogeneous, with some apparently haemorrhagic 
areas responding to the challenge (white arrows, 
Figure 2A) and others remaining unchanged. These 
findings are consistent with H&E sections, which 
show homogenous, poorly differentiated PC3 
tumours with a necrotic core (Figure 3A), as opposed 
to the well differentiated, haemorrhagic phenotype 
with stromal infiltration and viable core in the LNCaP 
tumours (Figure 3B). Quantification of spatial 
heterogeneity (see Supplementary Methods) in the 
tumour responding fraction image is significantly 
higher in LNCaP tumours (Figure 4A; LNCaP: 
0.57±0.02, nt=35, nb=17, PC3: 0.447±0.017, nt=53, 
nb=30; p<0.0001) and the metric of heterogeneity is 
robust to tumour size differences (Figure 4B-D). In 
both tumours, the regions that become well 
oxygenated after the challenge are not simply the 
areas with more blood in the static THb image. These 
data indicate that OE-OT reveals a complex dynamic 
picture of tumour vascular function and 
heterogeneity not available using static OT alone.  
 
 
Figure 3. PC3 and LNCaP tumours show significant differences in morphology, as well as vascular density and function, consistent with OE-OT findings. 
(A) Example fields of view from sections stained with H&E, immunofluorescent CD31 and unstained showing Hoechst fluorescence. H&E sections illustrate the characteristic 
presence of necrotic cores in PC3 tumours (red dashed arrow) and extensive haemorrhage in the LNCaP (black arrow, inset showing haemorrhage in an example LNCaP tumour 
after removing the skin). Distinct vascular density (CD31) and small molecule agent delivery capabilities (Hoechst) are apparent between the tumour types (n=14,6,25 PC3, 
n=5,5,25 LNCaP for necrosis, haemorrhage and fluorescence respectively). Each point represents the mean of the given metric over 4 sections for each biological replicate * 
p<0.05, ** p<0.01, *** p<0.001 by unpaired two-tailed t-test (unequal variances). Box between 25th and 75th percentile, line at median.  
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Figure 4. Quantification of spatial vascular heterogeneity within the tumours. (A) Box chart comparing the spatial heterogeneity parameter η for PC3 and LNCaP 
tumours. Example synthetic tumours together with the corresponding η values are shown to illustrate the numerical value of the parameter for a rim-core response to oxygen 
challenge (B), a scattered response (C), and for a smaller tumour (D) with the same scattered response distribution illustrating the independence from tumour size. * p<0.05, ** 
p<0.01, *** p<0.001, by unpaired two-tailed t-test (unequal variances), n=53 PC3, n=35 LNCaP. Box between 25th and 75th percentile, line at median. 
 
 
In the context of evaluating disease 
aggressiveness, we performed a preliminary 
examination of the few particularly fast and slow 
growing tumours within each of the PC3 and LNCaP 
cohorts. ΔSO2MSOT derived from the first imaging 
session (when the tumours had just reached > 30mm3) 
was significantly higher for those tumours that 
proceeded to grow more rapidly during the 
remainder of the experiment (PC3: nb=3 per group, 
p<0.001; LNCaP: nb=3 per group, p<0.05). 
Tumour response to OE-OT correlates with 
vessel perfusion and permeability 
Having established the robustness of the OE-OT 
metrics, we then explored their correlation with 
histopathological assessment of vascular density and 
function (Figure 3A). PC3 tumours show little CD31 
VF or Hoechst uptake on average (Figure 3B) and 
these parameters are uncorrelated (r=0.25, p=0.21, 
n=25); conversely, LNCaP tumours show high CD31 
VF and Hoechst uptake, which are positively 
correlated (r=0.63, p=0.02, n=14). Further supporting 
the low level of vascular functionality in PC3 
tumours, CAIX staining (indicative of tumour 
hypoxia) was over 3-fold higher in these tumours 
(0.63±0.03 n=6 vs. 0.19±0.03, n=5; p<10-5, Figure S8). 
Neither static OT nor dynamic OE-OT metrics 
extracted from the PC3 tumours correlate to CD31 VF 
(Table 1 left) indicating that not all PC3 tumour blood 
vessels are functional, as non-perfused vessels will 
not be seen by OT. SO2MSOT(O2) and ΔSO2MSOT show 
significant negative correlation to tumour necrotic 
fraction (Figure S9A; n=14; r=-0.67, p=0.008 and 
r=-0.61, p=0.02 respectively). In PC3 tumours, OE-OT 
metrics are strongly correlated to Hoechst uptake 
(Figure S9B), with negative correlations observed for 
Responding Fraction RF (r=-0.61, p<0.001, n=25), 
ΔSO2MSOT (r=-0.49, p=0.01, n=25) and T1/2 (r=0.52, 
p=0.02, n=20). SO2MSOT(O2) is positively correlated to 
CD31 Perfused Area (PA) in both tumours as 
expected (PC3: r=0.45, p=0.03, n=25; LNCaP: r=0.58, 
p=0.03, n=14). T1/2 could not be computed for 4 PC3 
tumours due to insufficient change in SO2MSOT over 
the background noise. As expected, these tumours 
showed a lower Hoechst intensity compared to the 
rest of the group (11.5±0.9 vs. 10.0±0.3, n=4 vs. n=22, 
low vs. high responders, p=0.09). LNCaP tumours 
(Table 1 right) show no significant relationships to 
tumour necrotic fraction (Figure S10A) or Hoechst 
uptake (Figure S10B). Unlike PC3 tumours, a positive 
correlation is observed between CD31 VF and 
Hb/THb (r=0.54, p=0.046/r=0.50, p=0.07, n=14), 
indicating that LNCaP vessels are more likely to be 
blood rich.  
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Table 1. Correlations of OT and OE-OT metrics to histology for PC3 and LNCaP tumours.  
 
Pearson r correlation coefficients are shown with relationships significant at a p<0.05 level highlighted in bold. Color-coding is designed to illustrate the magnitude and 
direction of the correlations (positive correlation = green, negative correlation = red). 
 
 
Figure 5. Magnetic resonance imaging indicates differences in K-trans and T2* between the tumour types (A) Total haemoglobin, as derived from static OT data, 
was the only metric to correlate with K-trans, as measured by DCE-MRI. Averaged changes in T2* (B) indicate a significant positive response to the oxygen gas challenge as 
measured by BOLD MRI. Representative images from both tumour types (C) show the spatial distribution patterns in the anatomical T2, T2*, KTrans and ΔSO2MSOT maps. * p<0.05, 
** p<0.01, *** p<0.001 by Pearson r correlation (A) or paired two-tailed t-test (B); n=7 PC3, n=5 LNCaP. 
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Figure 6. OE-OT derived hemodynamics highlights tumour rim-core 
disparity. SO2MSOT (A) and THb (B) in rim and core of PC3 (left) and LNCaP (right) 
tumours evolves differently, as evidenced by the significant difference in responding 
fraction (RF, C) and Hoechst Intensity (D). * p<0.05, ** p<0.01, *** p<0.001 by 
unpaired two-tailed t-test (unequal variances). n=27 PC3, n=12 LNCaP. Box between 
25th and 75th percentile, line at median. Air and oxygen breathing schedule in kinetic 
plots is indicated by purple and blue lines respectively. 
 
 
 
Figure 7. Depth dependence of static (OT) and dynamic (OE-OT) imaging 
response. (A) Mean values across all tumours illustrating the depth dependence of 
THb and OE-OT metrics, with example segmentation presented in (B) Tumour RF 
and ΔSO2MSOT have significant gradients with depth in both tumour types, as indicated 
schematically in (C). * p<0.05, ** p<0.01, *** p<0.001 by paired two-tailed t-test 
between first and last depth measurement; nt=34, nb=23 PC3, nt=7, nb=5 LNCaP. 
 
DCE- and BOLD-MRI were performed as 
surrogate markers of perfusion/permeability (via 
gadolinium uptake quantified with KTrans) and 
oxygenation (via deoxyhaemoglobin T2* effects) 
respectively (Figure 5). KTrans tended to be lower in 
PC3 tumours than LNCaP, in line with lower Hoechst 
uptake, although the trend was not significant 
(0.0014±0.0002s-1, n=7 vs. 0.0030±0.0008s-1, n=5, 
p=0.09). THb shows a strong correlation to transfer 
constant KTrans 47 in PC3 tumours (Figure 5A; r=0.95, 
p<0.003; n=7) but not in LNCaP (r=-0.26, p=0.67; n=5). 
No correlation with KTrans was observed in any OE-OT 
metrics, although a monotonic decrease in KTrans was 
observed with depth in both tumour types 
(0.0012±0.0003s-1 vs. 0.00078±0.00013s-1, n=7, p=0.09 
PC3 and 0.004±0.0008s-1 vs. 0.002±0.0002s-1, n=5, 
p=0.14 LNCaP). The T2* in PC3 tumours was 
significantly longer (0.0095±0.0008s vs. 
0.0024±0.0002s, p<10-5) indicating T2* shortening due 
to the large haemorrhage in LNCaP tumours. While 
the mean T2* shows significant changes in response to 
the oxygen challenge in both tumours (Figure 5B; 
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p<0.01 in both cases), no correlation was observed 
between T2* or ΔT2* and OT/OE-OT metrics on a 
per-tumour basis (p>0.18 in both cases). The high 
morphological heterogeneity of LNCaP tumours is 
also reflected in their T2 maps (Figure 5C). 
OE-OT reveals intra-tumour vascular 
heterogeneity 
 Finally, we examined the relationship between 
OE-OT metrics and vascular dynamics, investigating 
in detail the rim-core effects observed qualitatively in 
H&E sections in Figure 3. SO2MSOT(O2), Responding 
Fraction RF and ΔSO2MSOT all decreased significantly 
with an increase in PC3 tumour size, but were 
uncoupled from growth in LNCaP tumours (Figure 
S11; PC3 p<0.003; LNCaP p>0.12). This could not be 
explained by an increase in necrotic fraction, as there 
was no relationship in either tumour between size and 
necrosis (PC3: r=0.19, p=0.49; LNCaP: r=0.74, p=0.15). 
In an attempt to elucidate the underlying reason for 
these changes, we compared the OE-OT derived 
SO2MSOT (Figure 6A) and THb (Figure 6B) kinetics in a 
1 mm thick tumour rim and the remaining tumour 
core. These data reveal a dramatic rim-core effect in 
the PC3 tumours, with little OE-OT response in the 
core; the LNCaP tumour core responds, albeit with a 
lower magnitude and different kinetic profile 
compared to the rim. Both RF (Figure 6C) and 
Hoechst uptake (Figure 6D) are significantly higher in 
the rim compared to the core in both tumour types. 
The maturity of the vasculature, indicated by the ratio 
of ASMA and CD31 staining, was found to be 
significantly higher in the 0.5mm rim of PC3 tumours 
compared to the core (n=6, 0.149±0.010 vs. 
0.132±0.011; p=0.03). For LNCaP tumours, no 
significant difference was seen between rim and core 
(n=5 sections, 0.181±0.010 vs. 0.201±0.013; p=0.22) but 
LNCaP tumours showed significantly higher 
ASMA/CD31 than PC3 tumours (0.184±0.010 vs. 
0.132±0.011, p=0.0004). 
Segmenting the first 2mm of the rim in larger 
tumours into 0.5 mm concentric regions (see example 
Figure 7B) reveals a striking pattern: both RF and 
ΔSO2MSOT decrease monotonically with depth in both 
tumour types, while THb and SO2MSOT(O2) decrease 
only in PC3 tumours (Figure 7A). In vitro 
measurements indicated that PC3 cells have a 
significantly higher oxygen consumption than LNCaP 
cells (1.32±0.08 µs/min vs. 0.77±0.12 µs/min, p=0.006; 
see Supplementary Methods). Higher oxygen 
consumption could cause a steeper longitudinal 
oxygenation gradient in the PC3 tumours, which 
taken together with the poorer vascular function, 
further reinforces the rim-core disparity. These 
OE-OT findings support the differences in vascular 
function indicated in ex vivo analysis, with PC3 
tumour vessels being relatively mature and well 
perfused only in the rim (Figure 7B) while LNCaP 
tumour vessels are generally functional and perfused 
in both rim and core. 
Discussion 
Optoacoustic tomography (OT) is an emerging 
modality that reveals haemoglobin concentration and 
oxygenation with high spatial resolution and 
sensitivity. OT yields signals even in areas of very low 
haemoglobin concentration, such as the tumour core, 
which are often excluded from analysis in 
non-tomographic studies29,30,32. We hypothesized that 
by studying the dynamic response of the tumour 
vasculature to oxygen enhanced (OE)-OT, we would 
gain greater insight into tumour vascular dynamics 
and spatial heterogeneity, which could in future be 
applied in the context of prostate cancer diagnosis and 
staging48, as well as in assisting patient stratification 
for therapy. OE-OT provides non-invasive imaging of 
vascular function and heterogeneity, which we 
validated with ex vivo analysis, and shows high 
repeatability compared to the traditional static OT 
oxygenation measurements. To establish the potential 
of OE-OT and define the characteristics that can be 
measured with the technique, we tested two prostate 
cancer xenograft models. PC3 tumours have a hypoxic 
and necrotic core, with relatively low CD31 vessel 
density, poor ASMA/CD31 coverage and low 
Hoechst uptake when compared to the rim. 
Conversely, LNCaP tumours show only a minor 
rim-core effect, with LNCaP tumours overall 
exhibiting lower hypoxia and a much higher CD31 
vessel density, ASMA/CD31 coverage, Hoechst 
uptake and KTrans when compared to PC3 tumours. 
The LNCaP tumours were also highly haemorrhagic, 
with short T2* and large blood lakes visible on H&E. 
While static OT measurement of total 
haemoglobin revealed a higher blood content in 
LNCaP tumours, the static oxygenation metric 
SO2MSOT(Air), frequently used in the literature29,32,49 
was identical in the two tumour types, apparently 
insensitive to the striking differences in their 
vasculature. Importantly, OE-OT overcame this 
limitation and revealed highly significant differences 
between the two xenografts, complementing previous 
MRI studies that demonstrated the potential of an 
oxygen challenge to reveal additional insight into 
tumour haemodynamics and enhance contrast 
between models with distinct vascularity13,50 During 
OE-OT, the SO2MSOT signal in LNCaP tumours reaches 
a high plateau, reflecting the overall higher total 
haemoglobin concentration and lower oxygen 
consumption measured in the LNCaP than in PC3 
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cells. Only a mild rim-core effect was observed, 
evidenced in OE-OT metrics in vivo and Hoechst 
uptake ex vivo. The histopathological heterogeneity 
both within and between LNCaP tumours was 
revealed by a spatially heterogeneous response to the 
oxygen challenge in vivo (even in some regions of 
haemorrhage) with both OE-OT and MRI. Taken 
together, these data indicate that the OE-OT response 
of LNCaP tumours was consistent with a generally 
well perfused, viable tumour containing marked areas 
of haemorrhage. 
PC3 tumours exhibit a pronounced rim-core 
effect32,51 with little or no OE-OT response occurring 
in the hypoxic and necrotic core. OE-OT in the rim, 
however, reveals a rapid rise in SO2MSOT following the 
oxygen challenge, expected given the presence of 
higher ASMA/CD31 and KTrans in the rim vasculature. 
In functional vasculature, the influx of oxygenated 
blood results in vasoconstriction52, likely manifested 
in the initial SO2MSOT jump and associated drop in 
THb signal, due to a decrease in vascular area. Taken 
together, these data indicate that the OE-OT response 
of PC3 tumours was consistent with a hypoxic and 
necrotic core, but a mature and perfused rim 
vasculature. PC3s also show per-tumour correlations 
of OE-OT (but not OT) metrics to histopathological 
analysis, highlighting the added value of OE-OT. 
SO2MSOT(O2) shows a strong inverse relationship to the 
tumour necrotic fraction. Responding Fraction RF and 
T1/2 show a strong inverse relationship to Hoechst 
uptake. ΔSO2MSOT is modulated by both necrosis and 
Hoechst uptake. These histological correlations were 
not seen in the LNCaP tumours, most likely due to 
their haemorrhagic phenotype, which enforces a more 
diffusion-based oxygen delivery mechanism and 
marginalises the effect of vascular function. The 
LNCaP tumours appear to rely instead on high 
vascularisation and perfusion throughout the tumour 
mass; the Hoechst uptake in LNCaP was positively 
correlated to CD31 vessel density, indicating a largely 
perfused vascular network. To the best of our 
knowledge, this is the first study to perform biological 
validation of optoacoustic metrics by using 
correlations on a per-tumour basis. 
Spatial and temporal heterogeneity in the 
vasculature of clinical and experimental tumours is 
high2 but is considered to have substantial prognostic 
value53. In this regard, the spatial resolution of OE-OT 
provides unique insight into vascular heterogeneity. 
The hypoxic PC3 tumour core4 has been shown 
previously to exhibit reduced vascular volume and 
high permeability due to the secretion of angiogenic 
growth factors51. This would result in a steep 
oxygenation gradient in the tumour vasculature from 
rim to core, as observed. Hoechst uptake, used here to 
assess vessel function and providing a general 
indication of delivery of small molecule agents such 
as therapeutics, is a mixed measure of vascular 
perfusion and permeability; in the core it is most 
likely a reflection of high permeability of relatively 
immature core vasculature2, as confirmed by a low 
ASMA/CD31 coverage, resulting in a slow or 
negligible OE-OT response. This likely drives the 
inverse relationship between tumour Responding 
Fraction RF and Hoechst uptake. The PC3 tumour 
rims are likely to have high Hoechst uptake more due 
to high perfusion4, resulting from mature rim 
vasculature. The inverse relationship between T1/2 
and Hoechst uptake is clearly explained in this case, 
since tumour tissue with a short T1/2 is more similar to 
healthy tissue vasculature and hence should be well 
perfused. This vascular phenotype in the rim may also 
explain the negative ΔSO2MSOT measured in the core, 
as vasoconstriction and rapid oxygen consumption in 
the rim7 would result in decreased oxygen delivery in 
the core. OE-OT therefore reveals a complex picture of 
tumour vascular dynamics. 
The ability of OE-OT to reveal heterogeneity in 
vascular density and function during tumour 
development has broad clinical implications. A key 
unmet need in early cancer detection, especially in the 
prostate, is delineating those tumours that will 
progress to invasive disease from those that will 
remain indolent. In a preliminary analysis, we found 
that the magnitude of the response to the gas 
challenge was significantly higher in the first imaging 
session for those tumours that proceeded to grow 
rapidly (in both PC3 and LNCaP). If confirmed in a 
larger cohort of mice, given the prognostic 
significance of vascular heterogeneity and tumour 
hypoxia, OE-OT may potentially be applied in early 
disease to reduce overtreatment. Furthermore, the 
correlation between OE-OT metrics in PC3 tumours 
with Hoechst uptake suggests that OE-OT may have 
value in predicting delivery of small molecule 
therapeutic agents in specific tumour types, 
improving patient stratification for chemotherapy.  
We have shown that dynamic OE-OT metrics 
exhibit high repeatability, clearly outperforming the 
static metrics and providing a high degree of 
confidence in the precision of the measurements, 
which is crucial for clinical translation. Nonetheless, 
there remain some limitations that must be addressed 
in future studies. Tumour response to an oxygen 
challenge is a combination of several physiological 
phenomena, both systemic and local to the tumour. 
The observed oxygen saturation is influenced 
systemically by applied anaesthesia and locally by 
transport and consumption of oxygen in the tumour, 
depending on factors such as blood flow and pH54. 
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Taking OE-OT forward into clinical applications will 
remove the need for anaesthesia, but the influence of 
local factors will need to be understood. The method 
should be further validated in a more realistic 
transgenic tumour model, as the vascularisation of 
subcutaneous models differs from that of 
spontaneous tumours55. OE-OT metrics did not 
correlate with DCE- or BOLD-MRI when comparing 
mean values per-tumour. Spatial co-registration of the 
OE-OT and MRI data in a larger cohort may therefore 
be necessary to elucidate such relationships. To test 
the performance of OE-OT we chose to examine two 
tumour models with clear differences in 
aggressiveness and growth rates; as a result of the 
disparity in tumour volumes, size matching was not 
performed. Instead, the size dependence was 
examined and accounted for in our analysis. Our 
OE-OT data is not corrected for the effects of fluence; 
in the haemorrhagic LNCaP model spectral colouring 
may impact the absolute quantification of SO2. 
Methods to perform fluence correction of OT data 
have received only limited validation in vivo56; future 
work should aim to directly relate OT data to 
absorbed optical energy density and hence enable a 
direct readout of absolute SO2. 
There remains an unmet clinical need for 
visualisation and robust quantification of tumour 
vascular function in the context of assessing prognosis 
and therapeutic response in solid tumours. Significant 
advances have been made towards clinical application 
of optoacoustic imaging57. In prostate cancer, early 
results indicate that OT may be useful to distinguish 
malignant from benign disease58,48; development of 
transrectal clinical probes is underway59,60. 
Capitalizing on these recent advances in optoacoustic 
tomography, we have developed a non-invasive and 
clinically translatable technique to assess tumour 
vascular dynamics and heterogeneity without the 
need for intravenous injection of a contrast agent. Our 
OE-OT metrics can distinguish between PC3 and 
LNCaP tumours based on their vascular 
characteristics. OE-OT metrics showed high 
repeatability and correlated directly to tumour vessel 
function assessed ex vivo, directly relevant for prostate 
cancer staging and therapeutic monitoring, which has 
not been shown before in an optoacoustic study. 
Importantly, OE-OT reveals a complex 
spatiotemporal picture of tumour vascular function, 
enabling us to extract haemoglobin concentration and 
oxygenation from static OT, along with data related to 
vasoactivity, perfusion and permeability in OE-OT. 
OE-OT has been applied here in the preclinical 
setting, but with future hardware developments could 
be integrated into existing transrectal ultrasound 
probes for prostate cancer59,60, to improve 
non-invasive delineation of aggressive and indolent 
disease and assist with patient stratification for 
therapy48,61. 
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